Percheron Therapeutics (ASX:PER) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

PER 주식 개요

퍼체론 테라퓨틱스는 호주에서 새로운 안티센스 의약품을 연구 및 개발하는 회사입니다.

PER 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

위험 분석

수익은 향후 3년간 연평균 32.3% 씩 감소할 것으로 예상됩니다.

의미 있는 시가총액이 없습니다. ( A$77M )

의미 있는 수익이 없습니다. ( A$2M )

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

Percheron Therapeutics Limited 경쟁사

Recce Pharmaceuticals

ASX:RCE

AU$117.0m

Vitura Health

ASX:VIT

AU$42.0m

Argenica Therapeutics

ASX:AGN

AU$87.1m

Starpharma Holdings

ASX:SPL

AU$41.7m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Percheron Therapeutics
과거 주가
현재 주가	AU$0.10
52주 최고치	AU$0.12
52주 최저치	AU$0.052
베타	0.87
11개월 변경	17.65%
3개월 변경 사항	17.65%
1년 변경 사항	38.89%
33년 변화	-50.00%
5년 변화	2.04%
IPO 이후 변화	-95.83%

최근 뉴스 및 업데이트

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Jun 03

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13

Recent updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Jun 03

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

May 12

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Dec 23

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Jun 24

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Mar 11

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Nov 26

주주 수익률

	PER	AU Pharmaceuticals	AU 마켓
7D	1.0%	3.8%	1.1%
1Y	38.9%	98.5%	17.9%

수익률 대 산업: PER 지난 1년 동안 58.4 %를 반환한 Australian Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: PER 지난 1년 동안 9.6 %를 반환한 Australian 시장을 초과했습니다.

가격 변동성

Is PER's price volatile compared to industry and market?
PER volatility
PER Average Weekly Movement	7.7%
Pharmaceuticals Industry Average Movement	10.4%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.6%
10% least volatile stocks in AU Market	3.6%

안정적인 주가: PER 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: PER 의 주간 변동성( 9% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2000	n/a	James Garner	www.PercheronTx.com

퍼체론 테라퓨틱스는 호주에서 새로운 안티센스 의약품을 연구 및 개발하는 회사입니다. 이 회사의 제품 파이프라인에는 듀센 근이영양증, 사지 거들 근이영양증 R2, 다발성 경화증, 천식 및 기타 염증 적응증 치료를 위한 임상 2a상 시험 중인 CD49d의 안티센스 억제제인 ATL1102가 포함되어 있습니다. 또한 성장 호르몬 수용체 발현을 차단하여 혈중 인슐린 유사 성장 인자-I 호르몬 수치를 낮추고 과도한 성장 호르몬 작용과 관련된 질병을 치료하도록 설계된 성장 호르몬 수용체를 표적으로 하는 올리고뉴클레오티드인 아테시도르센(ATL1103)이 임상 2상 시험을 완료한 제품 파이프라인에 포함되어 있습니다.

Percheron Therapeutics Limited 기본 사항 요약

Percheron Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
PER 기본 통계
시가총액	AU$90.15m
수익(TTM)	-AU$11.92m
수익(TTM)	AU$2.97m

30.4x

P/S 비율

-7.6x

P/E 비율

PER 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
PER 손익 계산서(TTM)
수익	AU$2.97m
수익 비용	AU$62.15k
총 이익	AU$2.91m
기타 비용	AU$14.83m
수익	-AU$11.92m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.013
총 마진	97.91%
순이익 마진	-401.57%
부채/자본 비율	0%

PER 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

PER 주식 개요

보상

위험 분석

Percheron Therapeutics Limited 경쟁사

ASX:RCE

AU$117.0m

ASX:VIT

AU$42.0m

ASX:AGN

AU$87.1m

ASX:SPL

AU$41.7m

가격 내역 및 성능

최근 뉴스 및 업데이트

Consensus revenue estimates decrease by 40%

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Consensus EPS estimates upgraded to AU$0.022 loss

Price target increased by 7.1% to AU$0.30

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Recent updates

Consensus revenue estimates decrease by 40%

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Consensus EPS estimates upgraded to AU$0.022 loss

Price target increased by 7.1% to AU$0.30

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Consensus revenue estimates increase by 71%

New minor risk - Financial data availability

New major risk - Financial position

New minor risk - Shareholder dilution

Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK

We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide (ASO) to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency

Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD

Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe

Less than half of directors are independent

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study

Consensus forecasts updated

Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase

Full year 2022 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in FY 2021)

We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets

Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19

Antisense Therapeutics Limited Announces ATL1102 DMD Clinical Trial Application Submitted in Europe

Antisense Therapeutics Limited Announces Results from First Study of Antisense to CD49d in Limb Girdle Muscular Dystrophy R2 Mouse Model

Antisense Therapeutics Limited Announces the Results from A First Study of Antisense to CD49d in A Limb Girdle Muscular Dystrophy R2 (LGMDR2) Mouse Model

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Price target increased to AU$0.58

Antisense Therapeutics Limited Announces Dosing Commenced in MCRI Collaboration Animal Study

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Price target increased to AU$0.60

Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential

Forecast to breakeven in 2024

Price target increased to AU$0.54

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Antisense Therapeutics Limited Announces US FDA Feedback on Type C Meeting for ATL1102 in the US

Antisense Therapeutics Limited Announces Manufacture of ATL1102 clinical supplies for Phase IIb trial

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Announces the Paediatric Investigation Plan for ATL1102 in DMD Submitted to European Medicines Agency

Antisense Therapeutics Limited Announces Executive Changes

New 90-day high: AU$0.21

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Antisense Therapeutics Limited, Annual General Meeting, Dec 18, 2020

Antisense Therapeutics Limited Announces Statistically Significant Improvement in Pul2.0 with Atl1102 Treatment in Non-Ambulant Boys with DMD Compared to A Matched Natural History Control

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt

주주 수익률

가격 변동성

회사 소개

Percheron Therapeutics Limited 기본 사항 요약